I first noticed the name Theranos while walking by its facilities in Palo Alto, California, in 2014. That name was so intriguing that I searched Google to find it and learned that it supposedly combined the Greek words “therapy” and “diagnosis.” The basic vision was impressive: massive, inexpensive diagnostic testing using a new technology that could run hundreds of tests concurrently at very low cost and using tiny amounts of blood without a needlestick. The idea crossed my mind to consider collaborating with such avant-garde entrepreneurs in research studies.
Ioannidis JPA. Stealth Research and Theranos: Reflections and Update 1 Year Later. JAMA. 2016;316(4):389–390. doi:10.1001/jama.2016.6986
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: